Lpath volume and shares continue to rise; up 30% on buyout speculation

Shares of LPath LPTN rose 30.43% to $1.20+0.28 on the day before Wall Street takes a Thanksgiving break.

Last Thursday, November 17th, BioMedReports told readers about the firm, which appears to be a potential acquisition target for Big Pharma. 

The firm's therapeutics platform is showing strong data which suggests that their drug-discovery engine has a unique ability to bind to and inhibit bioactive lipids that contribute to various diseases. Pfizer  Morgan Joseph, a firm with research analysts who distinguish themselves by zeroing in on quality companies with growth prospects and which often present special situations, recently rated the firm a "Buy" with a price target of $8.

The Company's iSONEP drug candidate after published data shows that the drug appears to mitigate the scar tissues and inflammation associated with age-related macular degeneration. In fact, Phase 1 results suggest iSONEP might actually “melt away” less mature lesions and those with occult-type disease represent ~70-80% of the market, but close to 90% of the newly diagnosed patients. Pfizer PFE has recently established a partnership (possible $500+M) with the firm for their ocular drug candidate.
 

Shares are now only 22.58% from their 52-Wk high ($ 1.55 ), with very minor resistance to overcome at the $1.25 level.